The relation between expression of PDCD5 and androgen receptor in tissue of human prostate cancer
-
摘要: 目的:探讨PDCD5蛋白与雄激素受体(AR)在人类前列腺癌(PCa)组织中表达的相关性。方法:用EnVision法对29例PCa组织切片进行PDCD5及AR免疫组化染色,对其在PCa组织中表达的相关性进行统计学分析。结果:依据定性分析结果对PDCD5在AR(+)及AR(-)两组间PCa组织中的表达进行统计学分析显示两者间比较差异无统计学意义(P＞0.05),但PDCD5免疫组化染色定量分析提示PDCD5在PCa AR(+)组中表达明显强于AR(-)组(P＜0.01)。结论:PDCD5在PCa AR(-)组中的表达要弱于AR(+)组,提示AR缺失可能导致或伴随PCa细胞凋亡的进一步下调,进而引起AIPC/HRPC的发生。Abstract: Objective:To explore the relationship between PDCD5 and AR expressing in prostate cancer (PCa) tissues. Method:The expressions of PDCD5 and AR in 29 PCa samples were tested by EnVision immunohistochemical methods. 29 PCa samples were divided into AR(+) and AR (-) group, the expression of PDCD5 was compared between two groups. Result:According to the qualitative analysis,there was no statistical difference in expression of PDCD5 between AR(+) and AR(-) PCa tissues(P>0.05), but the statistical outcome of the quantitative analysis showed the intensity of immunohistochemistry staining of PDCD5 in AR(+) was obviously higher than AR(-) group(P<0.01). Conclusion:The expression of PDCD5 in PCa with AR(-) was obvious lower than that in PCa with AR(+), which suggests deletion of AR may be accompanied with or induce apotosis downregulation and cause AIPC/HRPC.
-
Key words:
- prostate cancer /
- PDCD5 /
- androgen receptor
-
-
[1] BANERJEE P P,BANERJEE S,BROWN T R.Bcl-2protein expression correlates with cell survival andandrogen independence in rat prostatic lobes[J].En-docrinology,2002,143:1825-1832.
[2] JI X,CHEUNG R,COOPER S,et al.Interferon al-fa regulated gene expression in patients initiating in-terferon treatment for chronic hepatitis C[J].Hepa-tology,2003,37:610-621.
[3] 李惠平,曹志敏,邵玉霞,等.重组人TFAR19蛋白与羟基喜树碱联用对人7721肝癌细胞周期和诱导凋亡的影响[J].北京医科大学学报,2000,32(5):408-410.
[4] 张岱,刘朝晖,李克敏,等.重组人PDCD5蛋白对干扰素γ诱导人宫颈癌SiHa细胞凋亡的增敏作用的初步探讨[J].中国妇产科临床杂志,2004,5(4):286-289.
[5] 刘朝晖,张岱,李克敏,等.PDCD5蛋白在正常宫颈、宫颈上皮内瘤样病变和宫颈癌中的表达[J].北京大学学报(医学版),2004,36(4):407-410.
[6] JEMAL A,SIEGEL R,WARD E,et al.Cancer sta-tistics,2007[J].CA Cancer J Clin,2007,57:43-66.
[7] PEYROMAURE M,DEBRB,MAO K,et al.Management of prostate cancer in China:a multi-center report of 6institutions[J].J Urol,2005,174:1794-1797.
[8] 邵常霞,项永兵,刘振伟,等.上海市区泌尿系统恶性肿瘤相对生存率分析[J].中国肿瘤临床,2005,32(6):321-324.
[9] SMALL E J,HARRIS K A.Secondary hormonalmanipulation of prostate cancer[J].Semin Urol On-col,2002,20(3Suppl 1):24-30.
[10] HEINLEIN C A,CHANG C.Androgen receptor inprostate cancer[J].Endocr Rev,2004,25:276-308.
[11] ABRAHAMSSON P A.Neuroendocrine cells intumour growth of the prostate[J].Endocr RelatCancer,1999,6:503-519.
[12] DEBES J D,TINDALL D J.The role of androgensand the androgen receptor in prostate cancer[J].Cancer Lett,2002,187:1-7.
[13] LIU H,WANG Y,ZHANG Y,et al.TFAR19,a novelapoptosis-related gene cloned from human leukemia cellline TF-1,could enhance apoptosis of some tumor cells in-duced by growth factor withdrawal[J].Biochem BiophysRes Commun,1999,254:203-210.
[14] 张颖妹,徐秀珍,刘红涛,等.人重组TFAR19蛋白对白血病细胞株HL-60的促凋亡效应[J].中国免疫学杂志,2000,16(1):8-11.
[15] 焦建峰,陈冠英,黄玫,等.rhTFAR19蛋白质对γ射线诱导MCF-7细胞周期及凋亡影响的初步研究[J].中华肿瘤杂志,2000,22(2):102-104.
[16] CHEN Y,SUN R,HAN W,et al.Nuclear translocationof PDCD5(TFAR19):an early signal for apoptosis[J]?FEBS Lett,2001,509:191-196.
[17] 施作霖,林艳清,张延榕,等.雄激素受体在良恶性前列腺组织中的表达及与细胞增殖凋亡的关系[J].中华病理学杂志,2000,29(5):375-376.
[18] 居小兵,薛冬,华立新,等.前列腺癌组织中雄激素受体的表达[J].现代泌尿外科杂志,2003,8(2):98-100.
[19] HEINLEIN C A,CHANG C.Androgen receptor in pros-tate cancer[J].Endocr Rev,2004,25:276-308.
[20] KINOSHITA H,SHI Y,SANDEFUR C,et al.Methyla-tion of the androgen receptor minimal promoter silencestranscription in human prostate cancer[J].Cancer Res,2000,60:3623-3630.
[21] 刁鑫伟,叶明福,陈正堂,等.113例前列腺癌AR与凋亡相关因子表达的研究[J].重庆医学,2006,36(6):518-520.
[22] FRIEDMAN A E.Can a single model explain both breastcancer and prostate cancer[J]?Theor Biol Med Model,2007,4:28.
-
计量
- 文章访问数: 43
- PDF下载数: 69
- 施引文献: 0
下载: